Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies.
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report.
The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest discovery agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all discovery stage partnering deals announced since 2016 including financial terms where available including over 3,900 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.
Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.
Chapter 5 provides a review of discovery stage deal making since 2016. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.
Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.
Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 8 provides a comprehensive listing of the top 25 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2016, where a contract document is available in the public domain.
Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2016.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2016.
In addition, a comprehensive appendix of all discovery deals since 2016 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 provide the reader with the following key benefits:
- In-depth understanding of discovery stage deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of discovery stage agreements with numerous real life case studies
- Insight into the terms included in a discovery stage agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 include:
- Trends in discovery stage dealmaking in the biopharma industry since 2016
- Analysis of discovery stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life discovery stage deals
- Access to over 3,900 discovery stage deals
- The leading discovery stage deals by value since 2016
- Most active discovery stage dealmakers since 2016
- The leading discovery stage partnering 2016
In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides comprehensive access to available deals and contract documents for over 3,900 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides the reader with the following key benefits:
- In-depth understanding of discovery stage deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 3,900 discovery stage deals together with contract documents if available
- Detailed access to actual discovery stage deals entered into by the leading 25 big pharma and big biotech companies along with other biopharma companies
- Analysis of the structure of discovery stage agreements with numerous real life case studies
- Identify leading discovery stage deals by value since 2016
- Identify the most active discovery stage dealmakers since 2016
- Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
TABLE OF CONTENTS
Chapter 1 – Introduction
Chapter 2 – Why do companies partner at discovery stage?
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals
Chapter 3 – Discovery stage deal strategies and structure
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
220.127.116.11. Discovery and preclinical stage partnering case studies
18.104.22.168.a. Case study 1
22.214.171.124.b. Case study 2
126.96.36.199.c. Case study 3
188.8.131.52.d. Case study 4
3.2.2. Partnering later in pharmaceutical/biotech
184.108.40.206. Clinical stage partnering case studies
220.127.116.11.a. Case study 5
18.104.22.168.b. Case study 6
22.214.171.124.c. Case study 7
126.96.36.199.d. Case study 8
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study 9
3.6.1.b. Case study 10
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study 11
3.7.1.b. Case study 12
Chapter 4 – Discovery stage partnering payment strategies
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
188.8.131.52. Conditionality of upfront payments
4.3.4. Convertible loans
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
184.108.40.206. Issues affecting royalty rates
220.127.116.11. Royalties on combination products
18.104.22.168.a. Case study 13
22.214.171.124. Guaranteed minimum/maximum annual payments
126.96.36.199. Royalty stacking
188.8.131.52. Royalties and supply/purchase contracts
4.3.11. Option payments
Chapter 5 – Trends in discovery stage deal making
5.2. Discovery stage partnering over the years
5.2.1. Attributes of discovery deals
5.3. Discovery stage partnering by deal type
5.4. Discovery stage partnering by disease type
5.5. Partnering by discovery stage technology type
5.6. Discovery stage partnering by most active company, 2016 to 2023
Chapter 6 – Payment terms for discovery stage partnering
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
6.4.2. Discovery stage deal upfront payments
6.4.3. Discovery stage deal milestone payments
6.4.4. Discovery stage royalty rates
Chapter 7 – Leading discovery stage deals
7.2. Top discovery stage deals by value
Chapter 8 – Top 25 most active discovery stage dealmakers
8.2. Top 25 most active discovery stage dealmakers
Chapter 9 – Discovery stage partnering contracts directory
9.2. Discovery stage deals with contracts 2016 to 2023
Chapter 10 – Discovery stage deal making by development stage
10.2. Deals by discovery stage
Appendix 1 – Discovery stage dealmaking by companies A-Z
Appendix 2 – Discovery stage dealmaking by industry sector
Appendix 3 – Discovery stage dealmaking by stage of development
Appendix 4 – Discovery stage dealmaking by therapy area
Appendix 5 – Discovery stage dealmaking by technology type
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for discovery stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Discovery stage partnering frequency 2016- 2023
Figure 7: Discovery stage partnering by deal type since 2016
Figure 8: Discovery stage partnering by disease type since 2016
Figure 9: Discovery stage partnering by technology type since 2016
Figure 10: Top 25 most active discovery stage dealmakers, 2016 to 2023
Figure 11: Review of median upfront payments for discovery stage deals
Figure 12: Review of median milestone payments for discovery stage deals
Figure 13: Review of median royalty payments for discovery stage deals
Figure 14: Discovery stage deals with a headline value
Figure 15: Discovery stage deals with an upfront value
Figure 16: Discovery stage deals with a milestone value
Figure 17: Discovery stage deals with a royalty rate value
Figure 18: Top discovery stage deals by deal value since 2016
Figure 19: Most active discovery stage dealmakers 2016 to 2023
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
1CellBiO, 1ST Biotherapeutics, 2A, 2seventy bio, 3B Pharmaceuticals, 3SBio, 3T Biosciences, 4basebio Discovery, 4B Technologies, 4C Biomed, 4D Molecular Therapeutics, 4D Pharma, 4E Therapeutics, 4P-Pharma, 7 Hills Pharma, 10X Genomics, 22nd Century, 23andMe, 48Hour Discovery, 221b Foundation, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, A*STAR Singapore Immunology Network, A*STAR’ Institute of Molecular and Cell Biology, A-Alpha Bio, A.I. Squared, A2A Pharmaceuticals, Aachen University, Aarhus University, Aarvik Therapeutics, AavantiBio, AAVnerGene, Abbisko Therapeutics, Abbvie, Abby Grace Foundation, Abcam, AbCellera Biologics, Abcuro, Abeona Therapeutics, Abera Bioscience, Abilita Bio, Ab Initio, Abintus Bio, Abiosciences, ABL Bio, Ablexis, Ablynx, Ab Magnitude Ventures, AbMed, Abmuno Therapeutics, Abound Bio, Aboundbio, Abpro, Abramson Cancer Center, AbSci, Absolute Antibody, Ab Studio, AbTis, ABVC BioPharma, Abveris, Abzena, Academic Drug Discovery Consortium, ACADIA Pharmaceuticals, AC Bioscience, Accelerate Technologies, Accelerator for Technological Research in Genomic Therapies, Acceleron Pharma, Accent Therapeutics, Accenture, ACEA Biosciences, Acerand Therapeutics, Acerta Pharma, Acetylon Pharmaceuticals, Achilles Therapeutics, AC Immune, Aclaris Therapeutics, Actelion, Actinium Pharmaceuticals, ACT Therapeutics, Actuate Therapeutics, Acucela, Acuitas Therapeutics, AcuraStem, Acurx Pharmaceuticals, Adagene, AdAlta, Adapsyn Bioscience, Adaptate Biotherapeutics, Adaptimmune, Adaptive Biotechnologies, Adaptive Phage Therapeutics, AdaptVac, Adcentrx Therapeutics, ADC Therapeutics, Addex Therapeutics, Adeptrix, Adicet Bio, Adimab, Adnab, AdoRx Therapeutics, Adrestia, ADT Pharmaceuticals, Aduro BioTech, Advaite, Advanced Proteome Therapeutics, Advaxis, AdventHealth, Adverum Biotechnologies, Adynxx, Aegis Life, Aelian Biotechnology, Aerogen, Aethlon Medical, Aethon Therapeutics, Aetion, Aevi Genomic Medicine, Aevitas Therapeutics, Affilogic, Affimed Therapeutics, Affini-T Therapeutics, Affinia Therapeutics, Affinity Biosciences, AffyXell Therapeutics, Afraxis, AgBiome, AGC Biologics, Age Labs, Agenus Bio, AgeX Therapeutics, Agilent Technologies, AgomAb Therapeutics, AgonOx, AHN Autoimmunity Institute, Aichi Medical University, AiCuris, AIkido Pharma, AimedBio, AIM ImmunoTech, Aimmune Therapeutics, Ainnocence, AiVita Biomedical, Ajinomoto, Akadeum Life Sciences, Akcea Therapeutics, Akers Biosciences, Akili Interactive Labs, Akouos, Akoya Biosciences, Akrevia Therapeutics, Akriveia Therapeutics, Akshaya Bio, Alamar Biosciences, Albany Molecular Research, Albert Einstein College of Medicine, Albumedix, Alchemab, Alderley Analytical, Aldevron, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, Alex’s Lemonade Stand Foundation, Aligos Therapeutics, AliHealth, AlivaMab Discovery Services, ALK-Abello, Alkermes, ALK Positive, All4Cure, Allakos, Allegheny General Hospital, Allele Biotechnology and Pharmaceuticals, Allen Institute for Brain Science, Allergan, Alliance for Cancer Gene Therapy, Alligator Bioscience, Allogene Overland Biopharm, Allogene Therapeutics, Alloplex Biotherapeutics, Allosteric Bioscience, AlloVir, Alloy Therapeutics, Allozymes, Almac Discovery, Almac Group, Almirall, Alnylam Pharmaceuticals, ALPHA10X, Alpha Biopharma, Alpha Cancer Technologies, Alphageneron Pharmaceuticals, Alpha Tau Medical, Alpine Immune Sciences, ALS Association, Altasciences, Alteogen, Alterity Therapeutics, Alveo Technologies, ALX Oncology, Alyatec, Alytas Therapeutics, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimer's Foundation of America, Alzheimer Society Research, Amagma Therapeutics, Amarna Therapeutics, Amathus Therapeutics, Amazon Web Services, Ambiopharm, Ambrx, Ambys Medicines, American Academy of Ophthalmology, American Association for Cancer Research, American BriVision, American Cancer Society, American Diabetes Association, American Lung Association, American Skin Association, American Society of Clinical Oncology (ASCO), American Society of Hematology, American Type Culture Collection (ATCC), Ametek, Amfora, Amgen, Amicogen, Amicus Therapeutics, AmMax Bio, Amphilix, Amphista Therapeutics, AMR, AMRA, AMRA Medical, Amunix, Amylyx Pharmaceuticals, Amyris, AnaBios, Anaeropharma, Analog Devices, Analytical Biological Services, Analytical BioSciences, Analytics Engines, AnaMar, ANANDA Scientific, Anavo Therapeutics, Anchiano Therapeutics, Anew Medical, AnGes MG, Angiogenesis Foundation, Angios, Anima Biotech, Anixa Biosciences, Anji Pharma, Ankarys Therapeutics, Ankyra Therapeutics, Annogen, Antengene, Anterios, Antibe Therapeutics, AntibioTx, Antibody Solutions, Antikor Biopharma, Antion Biosciences, Antios Therapeutics, Apeiron Biologics, Apellis Pharmaceuticals, Aphios, Apollo Therapeutics, Appia Bio, Applied Biology, Applied BioMath, Applied DNA Sciences, Applied Genetic Technologies, Applied StemCell, Applied Therapeutics, Aprecia Pharmaceuticals, APRINOIA Therapeutics, Aptahem, Aptamer Therapeutics, Aptinyx, Aptorum Group, Aptuit, Aqemia, Aqilion, Aquinnah Pharmaceuticals, Aquitaine Science Transfert (SATT Aquitaine), Aragen Bioscience, Aragen Life Sciences, Aravive Biologics, Arbele, Arbor Biotechnologies, Arbutus, ARCA Biopharma, Arcadia Biosciences, Arcellx, ARC Therapeutics, Arctic Vision, Arctoris, Arcturus Therapeutics, Arcus Biosciences, Ardeagen, Ardelyx, Ardent Mills, Ardigen, Arena Pharmaceuticals, Ares Genetics, Ares Life Sciences, argenx, Argobio, Argonne National Laboratory, Ariad Pharmaceuticals, Ariana Pharma, Aridis Pharmaceuticals, Ariel Precision Medicine, Arima Genomics, Arix Bioscience, Arizona State University, Ark Biosciences, Arnay Sciences, Aro Biotherapeutics, Arpeggio Biosciences, Arrakis Therapeutics, Array Biopharma, Arrevus, Arrow Pharmaceuticals, Arsenal Biosciences, Artelo Biosciences, Artes Biotechnology, Artialis, Artios Pharma, Artisan Bio, Artiva Biotherapeutics, Artizan Biosciences, Arvinas, Arzeda, Asahi Kasei, Asahi Kasei Pharma America, Asceneuron, ASC Therapeutics, Asieris Pharmaceuticals, ASKA Pharmaceuticals, Asklepios Biopharmaceutical, Assembly Biosciences, Associazione Poic e Dintorni APS, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, Asthma UK, AstraZeneca, Astrogen, AstronauTx, Asylia Therapeutics, ATAI Life Sciences, Atalanta Therapeutics, Atara Biotherapeutics, Atavistik Bio, aTen Therapeutics, Athenex, Athos Therapeutics, Atlante Biotech, Atlas Venture, Atomwise, ATP, Atrapos Therapeutics, Atreca, Atropos Therapeutics, ATUM, Atvio Biotech, aTyr Pharma, Auburn University, Audentes Therapeutics, AUM Biosciences, AUM Biotech, Aural Analytics, Auransa, Aurigene Discovery Technologies, Auron Therapeutics, Australian Department of Health and Ageing, Australian Foundation for Diabetes Research, Australian Research Council, Australian Research Data Commons, Autifony Therapeutics, Autigen, Autobahn Labs, Autodesk, Autolus, Autotelic BIO, Avacta, Avactis Biosciences, Avalon GloboCare, AvantGen, Avatamed, Avectas, Aviceda Therapeutics, Avidity Biosciences, Avista Therapeutics, Avrobio, Axcelead Drug Discovery Partners, Axcella, Axial Biotherapeutics, Axiogenesis, Axis Therapeutics, Axovant Gene Therapies, Axxam, AyoxxA Biosystems, Azitra, Azos Bio, AzurRx BioPharma, B-MoGen Biotechnologies, Babraham Institute, Bacit, Bactevo, BAKX Therapeutics, Barer Institute, Barrow Neurological Institute, Baruch S Blumberg Institute, BASF, Basilea Pharmaceutica, Batavia Biosciences, Battelle, Baudry Laboratory, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer CropScience, Baylor College, Baylor College of Medicine, BCD Bioscience, BC Platforms, Beacon Biosignals, Beacon Discovery, Beactica, Beam Therapeutics, Beartooth Therapeutics, BehaVR, BeiGene, Beijing Genomics Institute (BGI), Beijing Illness Challenge Foundation, Beijing Tide Pharmaceutical, Beijing University of Chinese Medicine, Belharra Therapeutics, Bellicum Pharmaceuticals, Ben-Gurion University, Benaroya Research Institute, BenevolentAI, Benitec Biopharma, Berg, Berkeley Lights, Beroni Group, Berry Genomics, Bertin Pharma, Beta Therapeutics, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Bethyl Laboratories, BGN Technologies, Bhami Research, Bharat Biotech, Bicycle Therapeutics, BigHat Biosciences, Bill and Melinda Gates Foundation, BIND Therapeutics, Bintai Kinden, Bio-Cancer Treatment International, Bio-Me, Bio-Rad Laboratories, Bio-Techne, BioAge Labs, BioArctic Neuroscience, biOasis Technologies, BIOASTER, BioAtla, BioBright, BioCardia, Biocept, Biocodex Microbiota Foundation, BioComo, BioCopy, BioCurate, BiocurePharm, Biocytogen, Biodextris, BioDuro, BioFluidica, Biofourmis, Biogen, Biognosys, Biohaven Pharmaceuticals, BioInvent, BioIVT, BioLegend, BioLite Japan, Biolojic Design, BioMap, BioMarin Pharmaceutical, Biomed Elements, Biomedical Advanced Research and Development Authority, Biomedical Primate Research Centre, BioMed X Innovation Center, bioMerieux, Biomica, Biomillenia, BioMotiv, Biomunex Pharmaceuticals, BiomX, BioNano Genomics, BiondVax, Bioneer, Bionetix, Bioniz Therapeutics, BioNova Pharmaceuticals, BioNTech, BionX Medical Technologies, Bio Palette, BioPharmics, BioPontis Alliance, Bioqube Ventures, Biorchestra, Biorelate, BioRestorative Therapies, Biortus Biosciences, Biosceptre International, Biosearch Technologies, Biosion, Biositu Pharmaceutical Technology, BioSkryb, BioSolveIT, BioSpherix, BioStrand, BioSymetrics, Biotechnology and Biological Sciences Research Council (BBSRC), Biotem, Biotheus, Biotools, BioVaxys, Bioverativ, BioVersys, Bioz, Bird Foundation, Bit Bio, BiVictriX Therapeutics, Black Diamond Therapeutics, Blackford, Blackfynn, Blacksmith Medicines, BlackThorn Therapeutics, BlinkBio, BliNK Biomedical, Bliss Biopharmaceutical, Blockchain Global, Bloom Science, Blu Biotech, Bluebird Bio, Bluebridge Technologies, Blue Buffalo Company, Blue Cross Blue Shield Association, Bluefield Innovations, Blueprint Medicines, BlueRock Therapeutics, Blue Water Vaccines, Boca Biolistics, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bohai Biomedical, Bolder BioPATH, Bolt Biotherapeutics, Bonbouton, Bone Therapeutics, Bonnie J. Addario Lung Cancer Foundation, Boragen, Boston Biomedical, BostonGene, Boston University, Boston University School of Medicine, Boulos and Cooper Pharmaceuticals, Bpifrance, Bracco Imaging, Brain & Behavior Research Foundation, Brain Biomarker Solutions in Gothenburg, Brain Science Foundation, BravoVax, BRCA Foundation, Breakthrough Health, Breath Diagnostics, BriaCell Therapeutics, BrickBio, Brickell Biotech, BridgeBio Pharma, Bridge Biotherapeutics, Bridge Medicines, BridGene Biosciences, Brigham and Women's Hospital, Bright Peak Therapeutics, Brightseed, Brii Biosciences, Bristol-Myers Squibb, British Pharmacological Society, Broad Institute, Broadwing Bio, Brooklyn ImmunoTherapeutics, Brown University, Buck Institute for Age Research, BullFrog AI, Bunker Pflanzenextrakte, Burnet Institute, Burning Rock, BurstIQ, Byondis, C4 Therapeutics, C4X Discovery, Cabaletta Bio, Caerus Discovery, Calcimedica, Calico, Calidi Biotherapeutics, California Institute for Biomedical Research, California Institute for Regenerative Medicine, California Institute of Technology, Calimmune, Calixar, Calviri, Calyxt, Cambridge Enterprise, Cambridge Quantum Computing, Camino Pharma, CAMP4 Therapeutics, CANbridge Pharmaceuticals, Cancer Australia, Cancer Genetics, Cancer Research Institute, Cancer Research UK, Canopy Biosciences, Cantabio Pharmaceuticals, Cantargia, Capnia, Capricor Therapeutics, Capsida Biotherapeutics, Capsigen, Captor Therapeutics, Caravan Biologix, Caraway Therapeutics, CARB-X, Carbiotix, Cardiff University, Cardiogen Sciences, Cardurion Pharmaceuticals, Care4Rare Consortium, Carepay, Caribou Biosciences, Carina Biotech, Caris Life Sciences, Carisma Therapeutics, Carmentix, Carmine Therapeutics, Carmot Therapeutics, Carna BioSciences, Carnot BioSciences, CaroGen, Carolina BioOncology Institute, Cartana, Carterra, Cartexell, Cartherics, Casdin Capital, Casebia Therapeutics, Case Western Reserve University, Casma Therapeutics, Castle Creek Biosciences, CasZyme, Catalent, Catamaran Bio, Catholic University Leuven, CavoGene LifeSciences, CBT Pharmaceuticals, CDR-Life, Ceapro, Cedars-Sinai Medical Center, Cedilla Therapeutics, CEITEC, Celdara Medical, CelerisTx, Celgene, Cell&Soft, Cell2in, Cell and Gene Therapy Catapult, Cellaria Biosciences, Cellarity, Cellecta, Cellect Biotechnology, Cellectis, Cellerant Therapeutics, Cellesce, Cellevolve Bio, Cellinfinity Bio, CELLINK, Cellkey, Cell Medica, Cell Mogrify, CellOrigin Biotech, Cell Signaling Technology, Celltech, Cellthera Pharma, Celltrion, Cellular Biomedicine, Cellular Dynamics International, Celmatix, Celonic, Celsius Therapeutics, Celularity, Centene, Center for Biomarker Research in Medicine, Center for Genomic Regulation, Center for Human Genetics and Laboratory Medicine, Center for Infectious Disease Research, Centessa Pharmaceuticals, Centogene, Centre for Cellular and Molecular Platforms, Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine, Centre for Commercialization of Regenerative Medicine (CCRM), Centre for Drug Research and Development (CDRD), Centre For Proteomic & Genomic Research, Centre Leon Berard, Century Therapeutics, Cepheid, Cerebras Systems, Cerecor, Cerevance, Cerevel Therapeutics, Certara, Cerveau Technologies, Ceva Sante Animale, Cevec Pharmaceuticals, CGA 369, Chamishi Therapeutics, Champions Oncology, Chan Zuckerberg Initiative, Charite Universitatsmedizin Berlin, Charles River Laboratories, CHDI Foundation, Checkpoint Therapeutics, Chelexa Biosciences, ChemAxon, ChemDiv, Chiesi Farmaceutici, Children's Heart Foundation, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's Hospital Of Wisconsin, Children's Medical Research Institute, Children's Mercy Hospital, Children's National Health System, Children's National Hospital, Chimeric Therapeutics, China-Singapore Guangzhou Knowledge City, China National Biotech Group (CNBG), China Southeast University, Chinese Academy of Agricultural Science, Chinese Academy of Sciences, Chinook Therapeutics, Chiome Bioscience, CHO Plus, Christian Doppler Research Association, Chronos Therapeutics, Chugai Pharmaceutical, Cicero Diagnostics, Cidara Therapeutics, Cincinnati Children’s Hospital Medical Center, Cinda Bio-Pharmaceutical, Circuit Clinical, Circuit Therapeutics, Citranvi Biosciences, City of Hope, Civetta Therapeutics, CK Life Sciences, Clalit Health Services, Clarity Pharmaceuticals, Clarus Therapeutics, Cleara Biotech, Clearbridge Biomedics, Clear Creek Bio, ClearLight Diagnostics, Clearmind Medicine, ClearPath, ClearPoint Neuro, Cleveland Clinic, Cleveland University Hospitals, Cloud Pharmaceuticals, Clover Biopharmaceuticals, Clover Therapeutics, Clovis Oncology, CM Life Sciences, CMT Research Foundation, CN Bio, CNS Pharmaceuticals, Co-Diagnostics, Coalition for Epidemic Preparedness Innovations, Coave Therapeutics, Cobra Biologics, Cocrystal Pharma, CODA Biotherapeutics, Codagenix, Code Biotherapeutics, Codex DNA, Codexis, Codiak BioSciences, Coeptis Therapeutics, COFCO Group, Cogia Biotech, Cognition Therapeutics, CogState, Cohen Veterans Bioscience, CoImmune, Cold Spring Harbor, Collaborative Trajectory Analysis Project, Collplant, Colombia Ministry of Health and Social Protection, Colorado Center for Personalized Medicine, Colorado State University, Columbia University, Columbia University Medical Center, Combined Therapeutics, Comera Life Sciences, Complete Phytochemical Solutions, Complix, Compugen, Concept Life Sciences, ConcertAI, Concr, Confo Therapeutics, Congenica, Conkwest, ConserV Bioscience, ConsortiaTX, Consortium AI, Contera Pharma, Context Therapeutics, Contour Therapeutics, ContraVir Pharmaceuticals, Convelo Therapeutics, CoreBiome, Corestem, Cornell University, Coronado Biosciences, Corporation for Biological Research, Corteva Agriscience, Cortexyme, Corvidia Therapeutics, Courtagen Life Sciences, Covalab, Covaris, Creative Destruction Lab, Creative Medical Technologies, Creoptix, Crescendo Biologics, Cresset, Crestone Pharma, Crestovo, CRISPR Therapeutics, Cristal Therapeutics, Critical Path Institute (C-Path), Crohn's and Colitis Foundation of America, Crossbeta Biosciences, Crown Bioscience, CSIRO, CSL Behring, CStone Pharmaceuticals, CtM Biotech, Cue Biopharma, Cullinan Oncology, Cumberland Emerging Technologies, Curable, Curadev Pharma, Curadigm, Curasan, Cure Duchenne, Cure Genetics, Cure Sanfilippo Foundation, Cures Within Reach, Curetis, CureVac, CVC, Cybin, Cyclenium Pharma, Cyclerion Therapeutics, Cyclica, Cyclotek, Cyclo Therapeutics, CYduct Diagnostics, Cynata Therapeutics, Cyrus Biotechnology, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, cytena, Cytocom, CytoImmune Therapeutics, CytoLynx Therapeutics, CytomX Therapeutics, Cytoo, CytoReason, CytoSen Therapeutics, Cytosurge, Cytovance Biologics, Cytovant Sciences, CYTOVIA Therapeutics, D. E. Shaw Research, D2M, DAAN Bio Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, Dalriada Drug Discovery, Dana-Farber Cancer Institute, Dana Farber Partners Cancer Care, Danaher, Danish Innovation Fund, Dante Labs, Dartmouth College, DarwinHealth, Datavant, David H. Koch Institute for Integrative Cancer Research, Da Volterra, DayTwo, Debiopharm, Decibel Therapeutics, deCODE Genetics, DeepCDR Biologics, Deepcell, Deep Genomics, Deep Longevity, Deerfield Management, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, DeGregorio Family Foundation, Deinove, Delta 4, Dementia Discovery Fund, Denali Therapeutics, Denovium, Department of Defence, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, Dermala, Dermelix Biotherapeutics, DestiNA Genomics, Devonian Health Group, Dewpoint Therapeutics, Diagnostic Robotics, DiamiR, Diamond Light Source, DiCE Molecules, Dicerna Pharmaceuticals, DiNAQOR, DIOSynVax, Disc Medicine, Discngine, Distributed Bio, DNA Script, DNAtrix, DNX Biopharmaceuticals, doc.ai, Dolomite Bio, Domainex, Domain Therapeutics, Door Pharmaceuticals, Dorian Therapeutics, DotBio, Dotmatics, Dow AgroSciences, Dragonfly Therapeutics, Dren Bio, Drexel University, Drugs for Neglected Diseases Initiative, Duality Biologics, Dualogics, Dualsystems Biotech, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, Dunad Therapeutics, DuPont Pharmaceuticals, Dyadic International, DyNAbind, Dynamic Combinatorial Chemistry, Dynavax Technologies, Dyno Therapeutics, DZNE German Center for Neurodegenerative Diseases, E-Scape Bio, E-Therapeutics, E.T. Horn, Eagle Genomics, Eberhard Karls University Tubingen, ECM Therapeutics, Ecole Polytechnique Federale de Lausanne, Edesa Biotech, Edico Genome, EdiGene, Edison Oncology, Editas Medicine, EditForce, eFFECTOR Therapeutics, eGenesis, Egle Therapeutics, Eikonizo Therapeutics, Eikonoklastes Therapeutics, Eirion Therapeutics, Eisai, Elaaj Bio, Elanco, Elasmogen, Element Biosciences, ElevateBio, Elevation Oncology, Elevian, Elicio Therapeutics, Eligo Bioscience, Eli Lilly, Elix, Elixirgen, Elpis Biomed, Elpiscience, ElsaLys Biotech, Elucidata, Elysium Health, Embark Biotech, EMD Serono, Emendo Biotherapeutics, Emergence Therapeutics, Emergent BioSolutions, Emergex Vaccines, Emery Pharma, Emory University, Empirico, Enamine, Enara Bio, EnBiotix, Endevica Bio, enGene, Engitix, Enigma Biomedical, Enleofen Bio, ENPICOM, Ensoma, Enterome Bioscience, Enterprise Ireland, Enthera, Envisagenics, Enzolytics, EpiAxis Therapeutics, EpiBiome, Epic Sciences, Epidemiologic Solutions, Epilepsy Society, EpimAb Biotherapeutics, EpiPharma, Epivax, EpiVax Therapeutics, Epizyme, Epsilogen, EQRx, Equillium, Eracal Therapeutics, Erasmus University Medical Center, ERS Genomics, Ervaxx, Escient Pharmaceuticals, EsoCap, Esophageal Cancer Awareness Association, Esperovax, Essex Bio-Technology, Eterna Therapeutics, eTheRNA immunotherapies, Ethos Veterinary Health, Ethris, ETH Zurich, Eucure Biopharma, Eureka Eurostars, Eureka Therapeutics, Eurocine Vaccines, Eurofins Discovery, Eurofins Genomics, European Equity Partners, European Investment Bank, European Laboratory Research & Innovation Group, European Molecular Biology Laboratory, European Union, European Union Regional Development Fund, Eutilex, Evaxion Biotech, EV Biologics, Evelo Biosciences, Evercyte, Everest Medicines, EVerZom, Evitria, Evommune, Evonetix, Evopoint Biosciences, EVOQ Therapeutics, Evotec, Evox Therapeutics, Evozyne, EVQLV, Evrys Bio, Evvivax, Exacis Biotherapeutics, Exagen Diagnostics, ExcellaBio, ExcellGene, ExCellThera, Excelra, Excision BioTherapeutics, Exelixis, Exicure, Exonics Therapeutics, Exosome Sciences, Expansion Therapeutics, Experimental Drug Development Centre, Experimental Therapeutics Centre of Singapore, Expesicor, ExpreS2ion Biotechnologies, ExScientia, Eyam Vaccines and Immunotherapeutics, F-Star, F-Star Therapeutics, F1 Oncology, Fabric Genomics, Facial Pain Research Foundation, Facio Therapies, Factor Bioscience, FairJourney Biologics, Fannin, Fate Therapeutics, Fauna Bio, Federal Ministry of Education and Research (BMBF), Federal Ministry of Health (Germany), Federation Bio, Feinstein Institute for Medical Research, Feldan Therapeutics, Femtogenix, Ferring Pharmaceuticals, Fibriant, Fibrogen, FibroGenesis, FightMND, Filament Health, FineImmune Biotechnology, Firebrand Therapeutics, FIT Biotech, Five Prime Therapeutics, Flagship Biosciences, Flamingo Therapeutics, Flaskworks, Flatiron Health, Florica Therapeutics, Florida Atlantic University Research, Florida International University, Flow Eighteen38, Flow Pharma, Fluidigm, Foghorn Therapeutics, Folia Biotech, Fondazione Telethon, Food and Drug Administration (FDA), Forendo Pharma, Forge Therapeutics, FORMA Therapeutics, Fortress Biotech, Forty Seven, FortySix Venture Capital, Fosun Kite Biotechnology, Fosun Pharmaceutical, Foundation Fighting Blindness, Foundation for Innovative New Diagnostics, Foundation for Sarcoidosis Research, Foundation for the Children of the Californias, Foundation Medicine, Foundation to Fight H-ABC, Foundery Innovations, Four Points Innovation, FOXG1 Research Foundation, FOXO BioScience, Frame Cancer Therapeutics, Francis Crick Institute, Fraunhofer Institute for Molecular Ecology (IME), Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Freenome, French National Institute for Agricultural Research, Frequency Therapeutics, Friedreichs Ataxia Research Alliance, Friends of FSH Research, Frontier Medicines, Front Range Biosciences, FSD Pharma, Fujifilm, FUJIFILM Cellular Dynamics, Fujifilm Diosynth Biotechnologies, Fujitsu Laboratories, Fujitsu Laboratories of America, Fulcrum Therapeutics, Fundacion Medina, Fundacion Progreso y Salud, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Fusion Antibodies, Fusion Pharmaceuticals, FuturaGene, FutureGen Biopharm, Fuzionaire, Fuzionaire Diagnostics, G1 Therapeutics, Gabriella Miller Kids First Data Resource Center, Gadeta, Gaeta Therapeutics, Gain Therapeutics, Galapagos, Galaxy Biotech, GamaMabs Pharma, GATC Health, Gatehouse Bio, Gateway for Cancer Research, GB Sciences, GC LabCell, GC Pharma, Gedeon Richter, GE Healthcare, Geisel School of Medicine at Dartmouth, Geisinger Health System, Gel4Med, Gemini Therapeutics, GEMoaB, GEn1E Lifesciences, Gen9, Genagon Therapeutics, GenAhead Bio, GeneBay, GeneCentric Therapeutics, Genechem, GeneCode, Genective, GeneData, GenEdit, GeneDX, Geneious Biologics, Genentech, Geneos Therapeutics, General Automation Lab Technologies, Generate Biomedicines, Generation Biotech, Generex Biotechnology, Generian Pharmaceuticals, GenesisCare, Genesis Therapeutics, Genestack, Genethon, Genetic Analysis, Genetic Leap, Genetics Research, Genetic Technologies, Genetron Health, Genevant Sciences, Genewiz, Genfit, GenFleet Therapeutics, Genialis, Genisphere, GenKOre, Genmab, Gennao Bio, Genocea Biosciences, Genome and Company, Genome BC, Genome Biologics, Genome Canada, Genome Insight, Genome Institute of Singapore, Genomenon, Genomic Biopharma, Genomics, Genomics England, Genomic Vision, Genoox, Genosco, Genosity, Genovis, genOway, Genpact, Genprex, Gensaic, GenScript Biotech, GenScript ProBio, GentiBio, Gentris, Genuity Science, Genzyme, George Mason University, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, George Washington University, GeoVax, German Cancer Research Center, German Federal Ministry of Education and Research, Gero, Gibson Oncology, Gicell, Gigagen, GigaMune, GI Innovation, Gilead Sciences, Ginkgo BioWorks, Gladstone Institutes, GlamorousAI, Glaxo Group, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Alzheimer's Platform (GAP), Global Antibiotic Research and Development Partnership, Global Blood Therapeutics, Global Cancer Technology, Global Genes, Global Genomics Group, Global Virus Network, GlycoMantra, GlycoNet, Glycostem Therapeutics, Glycotope Biotechnology, GlycoT Therapeutics, Glythera, GNA Biosolutions, Gnosis Bioresearch, GNS Healthcare, Goethe University Frankfurt, Golden Meditech, Goldfinch Bio, Goliver Therapeutics, Good Start Genetics, Good Therapeutics, Google, Gossamer Bio, GO Therapeutics, Government of Hong Kong, Government of Ireland, Government of South Korea, Gracell Biotechnologies, Grail, Gray Foundation, Gray Matter, Great Ormond Street Hospital (GOSH), Green Cross LabCell, Greenlight Biosciences, Griffith University, Grifols, Gritstone Bio, Grunenthal, GT Apeiron Therapeutics, GT Biopharma, Guangzhou Fanen Biotechnology, Guangzhou Institute of Respiratory Disease, Guangzhou Xiangxue Pharmaceutical, Guardant Health, Gubra, Gyroscope Therapeutics, H3 Biomedicine, Hackensack Meridian Health, Hackensack University Medical Center, Hadassah Medical Center, Haihe Laboratory of Cell Ecosystem, Hainan Sinotau Pharmaceutical, Hairy Cell Leukemia Foundation, Halberd, HaloVax, Halozyme Therapeutics, Hamad Bin Khalifa University, HanAll Pharmaceuticals, Hanmi Pharmaceutical, Hannover Medical School, Hansa Biopharma, Haplogen, Harbour Antibodies, Harbour Biomed, Harpoon Therapeutics, Harvard Medical School, Harvard Stem Cell Institute, Harvard T.H. Chan School of Public Health, Harvard University, HCW Biologics, HDT Bio, Health Holland, Healx, Heartseed, Heat Biologics, HebeCell, Hebrew University of Jerusalem, Heidelberg Pharma, HekaBio, Helen F Graham Cancer Center, Helius Medical Technologies, Helix, Helix BioPharma, Helmholtz Centre for Infection Research, Helmholtz Zentrum Munchen, Helomics, Helperby Therapeutics, Helsinn Healthcare, HemaCare, Hemogenyx, HemoShear, Henlius Biotech, Henry Ford Health System, Henry M. Jackson Foundation, HepaTx, Hereditary Neuropathy Foundation, Herlev Hospital, Herophilus, Hesperos, HiFiBio, Highlight Therapeutics, HighRes Biosolutions, Hillstream BioPharma, Hitachi, HitGen, HIV Interactions in Viral Evolution (HIVE) Center, Hoag Memorial Hospital Presbyterian, Hoffmann La Roche, Holobiome, Homology Medicines, Hong Kong Baptist University, Hong Kong Polytechnic University, Hong Kong University of Science & Technology, Honor Epic Enterprises, Hookipa Pharma, Hopstem Biotechnology, Horizon Discovery, Horizon Europe, Horizon Pharma plc, Horizon Therapeutics, Hospital for Special Surgery, Hoth Therapeutics, HotSpot Therapeutics, Howard Hughes Medical Institute (HHMI), Hsiri Therapeutics, HTG Molecular Diagnostics, Hubrecht Institute, Hubrecht Organoid Technology, Hudson Institute of Medical Research, Huma, Humabs BioMed, Human Cell Atlas, Humanigen, Hummingbird Bioscience, Hummingbird Diagnostics, Hunterian Medicine, Huyabio International, hVIVO, Hybridize Therapeutics, Hyundai Hope On Wheels, I-mab, IAMA Therapeutics, IASO Biotherapeutics, Iaso Therapeutics, Ibex Medical Analytics, iBio, IBM, IBM Watson Health, Icagen, Icahn School of Medicine at Mount Sinai, iCarbonX, Ichor Medical Systems, Iconic Therapeutics, IDBiologics, IDBS, IDEAYA Biosciences, Idorsia, iECURE, IFM Therapeutics, iGEM, iGenomix, Igentify, IGM Biosciences, IGNITE Immunotherapy, IIT-Istituto Italiano di Tecnologia, Ikanik Farms, Ikena Oncology, Iksuda Therapeutics, Iktos, Ildong Pharmaceutical, ILiAD Biotechnologies, Illumina, Imagia Cybernetics, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, Imcyse, Imec, iMetabolic Biopharma, IMIDomics, Immagene, Immatics Biotechnologies, ImmBio, Immix Biopharma, Immorna, Immugenyx, Immunaccel, Immune Biosolutions, ImmuneCyte Life Sciences, Immuneering, ImmuNext, Immunic, Immunitas Therapeutics, ImmunityBio, ImmunoBiochem, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunome, Immunomic Therapeutics, ImmunoPrecise Antibodies, ImmunoQure, ImmunOs Therapeutics, Immunscape, ImmunXperts, Immuron, Immusoft, Immusol, Immutep, IMPACT Therapeutics, Imperial College London, Imperial Innovations, Impetis Biosciences, Imugene, Imutex, IMV, Imvaq Therapeutics, In4Derm, INBRAIN Neuroelectronics, Inceptor Bio, Incyte, InDex Pharmaceuticals, Indiana Biosciences Research Institute, Indiana University, Indivumed, Industrial Technology Research Institute, Infection Innovation Consortium, Infectious Disease Research Institute (IDRI), Infex Therapeutics, Infinity Pharmaceuticals, InflamaCORE, Inflammasome Therapeutics, Inflection Biosciences, InfoChem, Inhibrx, Initium Therapeutics, INmune Bio, Innate Biologics, Innate Pharma, INNERVIA Bioelectronics, InnoCentive, Innoplexus, InnoRNA, Innosuisse, Innovate Biopharmaceuticals, Innovate UK, Innovative Genomics Initiative (IGI), Innovative Targeting Solutions, Innovent Biologics, Inotrem, Inovio, Inovio Pharmaceuticals, Inozyme Pharma, InProTher, Inserm, Inserm Transfert, Insilico Biotechnology, Insilico Medicine, Insitro, InSphero, Instem, Institut Bergonie, Institut Carnot CALYM, Institut Català d'Oncologia, Institut Curie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute for Research in Biomedicine, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for Systems Biology, Institute of Bioengineering of Catalonia, Institute of Cancer Research, Institute of Materia Medica, Institute of Molecular and Clinical Ophthalmology Basel, Institute Of Molecular Biotechnology, Institute of Neurodegenerative Diseases, Institute of Virology and Immunology, Institut Gustave Roussy, Institut Pasteur, Intas Pharmaceuticals, Integral Molecular, Integrated BioTherapeutics, Intel, IntelGenx, Intellegens, Intellia Therapeutics, Intelligence Advanced Research Projects Activity (IARPA), Intellikine, INTELLiSTEM, Intermountain Healthcare, International AIDS Vaccine Initiative, International Association for the Study of Lung Cancer, International Center for Genetic Engineering and Biotechnology, International Isotopes, International Myeloma Foundation, International Vaccine Institute (IVI), Interprotein, InterSystems, InterVenn, InteRx Biomedical, Intima Bioscience, IntoCell, Intravacc, Intrexon, iNtRON Biotechnology, InveniAI, Invenra, Inventia Life Science, Inventiva, Inventum Genetics, Invetx, Invitae, InVivo Therapeutics, iOncologi, Ionis Pharmaceuticals, IONTAS, Iota Biosciences, Iovance Biotherapeutics, iPrime Therapeutics, iProgen Biotech, Iproteos, Ipsen, IRBM, Isogenica, IsoPlexis, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Istituti Clinici Scientifici Maugeria, iTeos Therapeutics, ITM Isotopen Technologien, Itochu, iTolerance, Iveric Bio, Ixaka, Ix Therapeutics, J2H Biotech, Jackson Laboratory, Jacobio Pharmaceuticals, Jaguar Health, James Cook University, James Hutton Institute, Janssen-Cilag, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janux Therapeutics, Japan Agency for Medical Research and Development, Javelin Biotech, Jazz Pharmaceuticals, Jeffrey Modell Foundation, Jenner Institute, Jesse's Journey, Jewish General Hospital, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Jiangsu NHWA Pharmaceutical, Jing Medicine, Jitsubo, Jnana Therapeutics, John Hopkins University School of Medicines, Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation
For a full list of companies please contact us at firstname.lastname@example.org
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.